Clinical Trials | May 14, 2026
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
We are building an AI-native operating system for pharma sales and distribution
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
Pan-India multidisciplinary program aims to improve coordinated care for patients with chronic kidney disease and heart failure
Industry veteran to lead Brinton’s expansion across India and key Asia Pacific markets
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
